October 30, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Taiho Pharmaceutical, Sanofi-aventis Conclude Licensing Agreement for Oral Pyrimidine Fluoride-derived Anticancer Agent TS-1
 

Tokyo, July 10, 2006 (JCN) - Taiho Pharmaceutical and sanofi-aventis have signed a licensing agreement for TS-1, an anticancer agent developed by Taiho Pharmaceutical.

Under the agreement, which was announced on June 4, sanofi-aventis will receive the rights to develop and commercialize the agent worldwide, except in Japan and some Asian countries. Sanofi-aventis will make an upfront payment, milestone payments for development and royalties on futures sales to Taiho Pharmaceutical.

Going forward, sanofi-aventis will develop the agent under the name S-1 while receiving the supply from Taiho Pharmaceutical.

TS-1/S-1 is an oral pyrimidine fluoride-derived anticancer agent which has been available in Japan since 1999. It is indicated for the treatment of gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer and inoperable or recurrent breast cancer.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Taiho Pharmaceutical Co., Ltd. News  
  Taiho Pharmaceutical, Sanofi-aventis Conclude Licensing Agreement for Oral Pyrimidine Fluoride-derived Anticancer Agent TS-1  (July 10, 2006)
  Taiho Pharmaceutical Licensed to Develop and Sell ABRAXANE Anti-cancer Agent by American BioScience  (Nov 21, 2005)
  Yakult Honsha, Taiho Pharmaceutical to Call off Plan to Co-promote New Anticancer Agent Oxaliplatin  (Apr 6, 2005)
  Mikasa Seiyaku, Taiho Pharmaceutical to Form Business Alliance in OTC Drug Business  (Dec 9, 2004)
  Yakult Honsha, Taiho Pharmaceutical to Co-promote New Anticancer Agent  (Aug 6, 2004)


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)